Drugs / 580299
last change Apr 2017 re-read 2 minutes ago

580299

Vaccine

Developed for
human papilloma virus infection
Investigated by
GlaxoSmithKline

Trials 2 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT01381575 Jun 2011 → Jun 2012 human papilloma virus infection GlaxoSmithKline Completed No outcome recorded
Phase 41 trial
Phase 4 NCT01031069 Oct 2010 → Jan 2016 human papilloma virus infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as 580299 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01381575
1

NCT01031069

Modality Vaccine “HPV vaccineNCT01381575
Route Intramuscular “vaccine administered intramuscularly” NCT01381575